# Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions

> **NCT02968394** · NA · UNKNOWN · sponsor: **The University Clinic of Pulmonary and Allergic Diseases Golnik** · enrollment: 11 (estimated)

## Conditions studied

- Allergy
- Bee Venom
- Immunotherapy
- Omalizumab

## Interventions

- **DRUG:** omalizumab

## Key facts

- **NCT ID:** NCT02968394
- **Lead sponsor:** The University Clinic of Pulmonary and Allergic Diseases Golnik
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-03
- **Primary completion:** 2017-03
- **Final completion:** —
- **Target enrollment:** 11 (ESTIMATED)
- **Last updated:** 2016-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02968394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02968394, "Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02968394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*